Drug combination testing in acute lymphoblastic leukemia using the MTT assay

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Drug resistance is a major challenge in treating acute lymphoblastic leukemia (ALL).
• Understanding drug interactions is crucial for optimizing chemotherapy regimens.
• The MTT assay is a potential tool for evaluating drug combinations in vitro.

Purpose of the Study:

• To investigate drug interactions in acute lymphoblastic leukemia (ALL) using the MTT assay.
• To evaluate three specific drug combinations: prednisolone (PRD) with vincristine (VCR), mafosfamide (MAF), and daunorubicin (DNR).
• To assess the heterogeneity of drug interactions across different patients, combinations, and concentrations.

Main Methods:

• Utilized the MTT assay to test drug combinations at 8-12 concentrations in ALL samples from 34 pediatric patients.
• Analyzed 518 comparisons of expected versus observed leukemic cell survival.
• Assessed interactions including synergism, antagonism, and additivity for each combination.

Main Results:

• Drug interactions exhibited significant heterogeneity between patients, drug combinations, and concentrations.
• PRD+VCR showed 46% synergism, 18% antagonism; PRD+MAF showed 51% synergism, 20% antagonism.
• PRD+DNR demonstrated 35% synergism and 31% antagonism, with less frequent synergism compared to the other combinations.
• While PRD+DNR showed more antagonism overall, the magnitude was not significantly different across combinations when all samples were pooled.

Conclusions:

• The MTT assay is a viable method for studying in vitro drug interactions in ALL.
• Drug interaction types (synergism, antagonism, additivity) vary significantly based on the specific drug combination, concentration, and individual patient.
• PRD+VCR and PRD+MAF combinations generally resulted in additive or synergistic effects, whereas PRD+DNR did not show markedly increased cytotoxicity over single agents.